The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine
{{output}}
Patients with myelodysplastic syndrome who fail hypomethylating agents have a very short median survival and about 25% risk of disease transformation to acute myeloid leukemia. We report our experience with low-dose protracted oral clofarabine in one patient w... ...
